Pharmaceutical Executive
In response to concerns about the low level of patient participation in clinical trials, the British Medical Association has launched an internet resource aimed at encouraging more patients to take part. Aimed at healthcare professionals, the site explains how different types of trials are conducted and spells out their ethical and best practices requirements.
In response to concerns about the low level of patient participation in clinical trials, the British Medical Association has launched an internet resource aimed at encouraging more patients to take part. Aimed at healthcare professionals, the site explains how different types of trials are conducted and spells out their ethical and best practices requirements.
BMA's head of science and ethics, Dr. Vivienne Nathanson, warns that low patient participation can hinder medical research. She says, "The involvement and cooperation of doctors and patients is crucial to the success of a clinical trial."
The site includes several initiatives that should increase the number of trial participants, including links to online registers, where patients can find details of studies suitable for them. It also suggests to their doctors that they take part. One of the initiatives mentioned in the resource is that patients should be able to access online trial registers, so they can find out what trials are taking place. That way, they can suggest to their doctor that they would like to participate
The site also recommends that healthcare providers give internet resources for clinical trials more widespread publicity, such as in hospital waiting rooms and doctors' offices.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.